Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927889 | PMC |
| http://dx.doi.org/10.3324/haematol.2020.278224 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Molecular measurable residual disease by immunoglobulin gene rearrangements on circulating tumor DNA predicts outcome in diffuse large B-cell lymphoma.
Haematologica
December 2024
Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome.
In diffuse large B-cell lymphoma (DLBCL) treatment response relies on imaging. We investigated the potential value of molecular measurable residual disease (MRD) on circulating tumor DNA (ctDNA) to predict patient outcomes. We retrospectively evaluated 73 patients.
View Article and Find Full Text PDFA novel prognostic nomogram based on imaging and molecular parameters for newly diagnosed extranodal natural killer/T-cell lymphoma patients.
Haematologica
August 2024
Medical Center of Hematology, Xinqiao Hospital, Army Medical University, Chongqing, 400038, China; State Key Laboratory of Trauma and Chemical Poisoning, Chongqing Key Laboratory of Hematology and Microenvironment, Jinfeng Laboratory, Chongqing, 401329, China; National Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
Not available.
View Article and Find Full Text PDFCheckpoint inhibition enhances cell contacts between CD4 T cells and Hodgkin-Reed-Sternberg cells of classic Hodgkin lymphoma.
Haematologica
October 2024
Dr. Senckenberg Institute of Pathology, Goethe University Frankfurt am Main, Theodor-Stern-Kai 7, D-60590 Frankfurt a. Main.
Although checkpoint molecules like CTLA-4 and PD1 have been described several years ago, checkpoint inhibitors such as nivolumab (an anti-PD-1 antibody) have only recently been used to treat classic Hodgkin lymphoma (cHL). Several studies have shown convincing therapeutic effects of nivolumab in cHL. However, the mechanism of action of nivolumab in cHL is not fully understood.
View Article and Find Full Text PDFClinical phenotype of adult-onset systemic histiocytosis harboring in-frame deletions.
Haematologica
September 2024
Paris-Saclay University, Versailles SQY University, Assistance Publique-Hôpitaux de Paris, Ambroise-Paré Hospital, Smart Imaging, Service de Pathologie, Boulogne.
Differences in venous clot structures between hemophilic mice treated with emicizumab factor VIII or factor VIIIFc.
Haematologica
June 2024
Laboratory for Hemostasis, Inflammation and Thrombosis, Unité Mixed de Recherche 1176, Institut National de la Santé et de la Recherche Médicale, Université Paris-Saclay, 94276 Le Kremlin-Bicêtre, France; CC and PJL contributed equally to this study.
Article Synopsis
- Recombinant factor VIII (rFVIII), rFVIIIFc, and emicizumab are treatments for hemophilia A, but they work in different ways which can affect how blood clots form.
- A study showed that clots formed with emicizumab were less stable compared to those made with rFVIII, and they looked different under a microscope.
- Researchers found that while emicizumab created more fibrin quickly, it took longer for the clots to stabilize and form well-structured fibers, leading to clots that were thicker but less organized and had fewer red blood cells in them.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!